Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H7HLAII DNA Vaccine for Pandemic Influenza
NCT06046092Phase 1Unknown
- Sponsor
- Oslo University Hospital
- Start
- Jul 2023
- Primary completion
- Dec 2024
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of H7HLAII in Influenza A virus infection (IAV) (3 arms), sponsored by Oslo University Hospital. Primary endpoints: Solicited adverse events following vaccination at 10 days and Abnormalities in physical examination, vital signs, and clinical laboratory tests at 6 months. Status: unknown.
02
Drugs
H7HLAII
03
Conditions
Influenza A virus infection (IAV)
Beyond the preview
Go deeper on NCT06046092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06046092.